Date Title Description PDF
29 Apr 2021 On business and financial situation The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States.     Download
12 Apr 2021 On business and financial situation The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. Download
02 Mar 2021 On business and financial situation The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download
02 Mar 2021 On business and financial situation The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download
24 Feb 2021 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download

Pages

Date Title Description PDF
15 Feb 2022 On business and financial situation ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. Download
14 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 Download
07 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 31 January 2022 and 4 February 2022 Download
31 Jan 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 24 January 2022 and 28 January 2022 Download
24 Jan 2022 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 17 January 2022 and 21 January 2022 Download

Pages

Date Title Description PDF
04 Apr 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the first quarter of 2019 Download
19 Mar 2019 R&D: new licenses, patents and registered trademarks ROVI Announces Positive Topline Results from Phase 3 study of Doria® in Patients with Schizophrenia Download
26 Feb 2019 Informe Anual de Remuneraciones de los Consejeros ROVI releases the 2018 annual report regarding remuneration of the members of the Board of Directors  Download
26 Feb 2019 Informe Anual de Gobierno Corporativo ROVI releases the 2018 Annual Corporate Governance Report Download
26 Feb 2019 Otros sobre gobierno corporativo The Company informs about the agreements adopted by the Board of Directors Download

Pages